Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients

References

• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics–2017 update: a report from the American Heart Association. Circulation 2017;135:e146–e603
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–6
   PubMed Web of Science ®Google Scholar
• Bell EJ, Lutsey PL, Basu S, et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med 2016;129:339 e19–26
   Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–76
   Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139–51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981–92
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104
   PubMed Web of Science ®Google Scholar
• Bengtson LGS, Lutsey PL, Chen LY, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol 2017;69:868–76
   PubMed Web of Science ®Google Scholar
• Bikdeli B, Abou Ziki MD, Lip GY. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost 2017;43;849–863
   PubMed Web of Science ®Google Scholar
• Enga KF, Rye-Holmboe I, Hald EM, et al. Atrial fibrillation and future risk of venous thromboembolism: the Tromso study. J Thromb Haemost 2015;13:10–16
   PubMed Web of Science ®Google Scholar
• Wang CC, Lin CL, Wang GJ, et al. Atrial fibrillation associated with increased risk of venous thromboembolism. A population-based cohort study. Thromb Haemost 2015;113:185–92
   PubMed Web of Science ®Google Scholar
• Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet 2009;373:155–66
   PubMed Web of Science ®Google Scholar
• Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation pathophysiology: implications for management. Circulation 2011;124:2264–74
   PubMed Web of Science ®Google Scholar
• Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425–34
   PubMed Web of Science ®Google Scholar
• Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631–9
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients. Chest 2012;141:e278S–e325S
   PubMed Web of Science ®Google Scholar
• Hansen L. The Truven Health MarketScan Databases for life sciences researchers. Ann Arbor, Michigan: Truven Health Analytics, IBM Watson Health; 2017. Available at: https://truvenhealth.com/Portals/0/Assets/2017-MarketScan-Databases-Life-Sciences-Researchers-WP.pdf [Last accessed August 24, 2017]
   Google Scholar
• Jensen PN, Johnson K, Floyd J, et al. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):141–7
   PubMed Web of Science ®Google Scholar
• Garg RK, Glazer NL, Wiggins KL, et al. Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data. Pharmacoepidemiol Drug Safety 2011;20:313–16
   PubMed Web of Science ®Google Scholar
• Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments. An application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008;19:766–79
   PubMed Web of Science ®Google Scholar
• Bergstralh EK, J. GMATCH macro. Rochester, Minnesota; 2003. Available at: http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locally-written-sas-macros [Last accessed April 2017]
   Google Scholar
• Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19–25
   PubMed Web of Science ®Google Scholar
• White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998;128:737–40
   PubMed Web of Science ®Google Scholar
• Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women’s Health Initiative. Am J Epidemiol 2004;160:1152–8
   PubMed Web of Science ®Google Scholar
• Kniffin WD, Jr., Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861–6
   PubMedGoogle Scholar
• Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005;43:480–5
   PubMed Web of Science ®Google Scholar
• Tamariz L, Harkins T, Nair V. Mini-sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: venous thromboembolism report. White Oak, Maryland: Mini-Sentinel; 2011
   Google Scholar
• Fang MC, Fan D, Sung SH, et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study. Med Care 2017;55:e137–e143
   PubMed Web of Science ®Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011;20:560–6
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130–9
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263–72
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512–22
   PubMed Web of Science ®Google Scholar
• Bross ID. Spurious effects from an extraneous variable. J Chronic Dis 1966;19:637–47
   PubMedGoogle Scholar
• Bergstralh E, Kosanke J. Locally written SAS macros: GMATCH. Rochester, Minnesota; 2003. Available at: http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locally-written-sas-macros [Last accessed March 15, 2017]
   Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149:315–52
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342–52
   PubMed Web of Science ®Google Scholar
• Einstein Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–510
   PubMed Web of Science ®Google Scholar
• Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406–15
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799–808
   PubMed Web of Science ®Google Scholar
• Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764–72
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368:709–18
   PubMed Web of Science ®Google Scholar
• Raskob G, Ageno W, Cohen AT, et al. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol 2016;3:e228–36
   PubMed Web of Science ®Google Scholar
• Salem JE, Sabouret P, Funck-Brentano C, et al. Pharmacology and mechanisms of action of new oral anticoagulants. Fundam Clin Pharmacol 2015;29:10–20
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016;176:1662–71
   PubMed Web of Science ®Google Scholar
• Chan Y-H, Kuo C-T, Yeh Y-H, et al. Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation. J Am Coll Cardiol 2016;68:1389–401
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest 2016;150:1302–12
   PubMed Web of Science ®Google Scholar
• Maura G, Blotière P-O, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 2015;132:1252–60
   PubMed Web of Science ®Google Scholar
• Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014;53:1–16
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 2016;5(6):e003725
   Google Scholar
• Lavoie K, Turgeon M-H, Brais C, et al. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. Journal of Atrial Fibrillation. 2016 12/31;9(4):1478. doi: 10.4022/jafib.1478. PubMed PMID: PMC5673313
   PubMedGoogle Scholar
• Barra ME, Fanikos J, Connors JM, et al. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. The American Journal of Medicine. 2016;129(11):1198–1204
   PubMed Web of Science ®Google Scholar
• Yao X, Shah ND, Sangaralingham LR, et al. Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology. 2017;69(23):2779–2790
   PubMed Web of Science ®Google Scholar
• Schulman S, Singer D, Ageno W, et al. NOACs for treatment of venous thromboembolism in clinical practice. Thromb Haemost. 2017;117:1317–1325
   PubMed Web of Science ®Google Scholar
• Fang MC, Fan D, Sung SH, et al. Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study. Med Care 2017 Dec;55(12):e137–e143
   PubMed Web of Science ®Google Scholar
• Sanfilippo KM, Wang T-F, Gage BF, et al. Improving Accuracy of International Classification of Diseases Codes for Venous Thromboembolism in Administrative Data. Thrombosis research. 2015;135(4):616–620
   PubMed Web of Science ®Google Scholar
• Parks AL, Redberg RF. Dabigatran compared with rivaroxaban vs warfarin—reply. JAMA Internal Medicine. 2017;177(5):744
   PubMed Web of Science ®Google Scholar